RTI International said today it will make an undisclosed investment in PierianDx and provide it with strategic support toward advancing adoption of its cloud-based clinical genomics software platform.
The value of the collaboration and specifics of the support were not disclosed.
RTI International said the collaboration with PierianDx was aimed at helping translate complex genomic data into actionable clinical insights to advance precision medicine.
Headquartered in North Carolina’s Research Triangle Park, RTI International is an independent, nonprofit institute that provides research, development, and technical services to government and commercial clients worldwide, in health and other areas. RTI maintains 12 U.S. and 12 overseas offices, and finished last year with $972 million in revenue and 3,852 projects for 1,198 clients.
“PierianDx's enabling technology is well aligned with our strategic investment program and RTI's mission to improve the human condition by turning knowledge into practice,” RTI International President and CEO Wayne Holden, Ph.D., said in a statement.
St. Louis-based PierianDx, which also has an office in Pune, India, spun out of Washington University in St. Louis in 2014. PierianDx has developed the Clinical Genomics WorkSpace (CGW), a cloud-based clinical genomics software platform designed to create streamlined, accurate analysis, interpretations and reporting for clinical labs. By integrating cloud-based software and clinical lab enablement services, the company aims to simplify the process of translating genomic data into patient-specific diagnosis and treatments.
The company also maintains a PierianDx Partner Sharing Network of more than 50 partners, including leading academic medical centers, cancer centers and health systems. Partners use shared genomic data to target patient-specific diagnosis and treatments for cancers and hereditary diseases.
The platform applies the company’s Clinical Genomics KnowledgeSpace, which produces patient-specific reports and visualization of data translated from public sources, as well as shared interpretations from partners, enhanced by a team of variant scientists and medical directors who contribute to the shared interpretations and support customers with validation and interpretation services.
“We are very excited to collaborate with RTI on numerous fronts, and welcome the partnerships and research capabilities they bring in the healthcare sector,” added Rakesh Nagarajan, founder and CEO of PierianDx. “The collaboration between RTI and PierianDx will be a catalyst to advance molecular testing methodologies and precision medicine programs worldwide.”
